<DOC>
	<DOCNO>NCT00617084</DOCNO>
	<brief_summary>The RESOLUTE-III Allcomers trial prospective , multicenter , randomize , two-arm , international , non-inferiority , open-label study 2300 patient 15-20 center . The study `` real world , comer '' study . Primary objective : compare Medtronic Endeavor-Resolute ( Zotarolimus-Eluting stent ) system Abbott XIENCE V ( Everolimus-Eluting stent ) system respect cardiac death , myocardial infarction ( clearly attributable non-target vessel ) , Target Lesion Revascularization 1 year `` real world '' patient population .</brief_summary>
	<brief_title>Randomized , Two-arm , Non-inferiority Study Comparing Endeavor-Resolute Stent With Abbot Xience-V Stent</brief_title>
	<detailed_description>The RESOLUTE-III Allcomers trial prospective , multicenter , randomize , two-arm , international , non-inferiority , open-label study 2300 patient 15-20 center . The study `` real world , comer '' study . Primary objective : compare Medtronic Endeavor-Resolute ( Zotarolimus-Eluting stent ) system Abbott XIENCE V ( Everolimus-Eluting stent ) system respect cardiac death , myocardial infarction ( clearly attributable non-target vessel ) , Target Lesion Revascularization 1 year `` real world '' patient population . Study hypothesis : To determine whether Zotarolimus-Eluting stent ( Medtronic Endeavor-Resolute ) non-inferior Everolimus-eluting stent ( Abbott XIENCE V ) term primary endpoint 12 month stent implantation .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Minimal age 18 year Symptomatic coronary artery disease Patient acceptable candidate treatment drug elute stent accordance applicable guideline Presence one coronary artery stenosis &gt; 50 % reference diameter 2.254.0mm cover one multiple stent Patient indication , lesion length vessel diameter accord 'Instructions Use ' study stent Patient willing able cooperate study procedure require follow visit patient legal representative inform agree sign EC approve write informed consent . Women childbearing potential negative pregnancy test within 7 day procedure woman lactate Known intolerance aspirin , clopidogrel ticlopidin , heparin , cobalt , nickel , chromium , molybdenum , polymer coating , Zotarolimus , Everolimus , contrast material Participating trial reach primary endpoint Planned surgery within 6 month PCI unless dual antiplatelet therapy maintain throughout perisurgical period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Drug Eluting Stents</keyword>
	<keyword>Interventional Cardiology</keyword>
</DOC>